Implant Placement in Combination With Connective Tissue Grafting (CTG_implant)

November 1, 2018 updated by: Danae A. Apatzidou, Aristotle University Of Thessaloniki

Tissue Changes Following Connective Tissue Grafting and Two-stage Implant Placement. A Randomised Clinical Trial

Suitable subjects who were in need of implant placement were randomised between two groups; Group-A (NA=23) received crestal implant placement. In Group-B (NB=23) a CTG harvested from the palate was stabilised over the implant-neck. At the time of implant placement (T0), Groups were categorized as having thin mucosa ≤2.5mm at the surgical site, or thick mucosa >2.5mm. Mucosa thickness, width of keratinised tissue (WKT), crestal bone levels and bone thickness were determined at T0 and at the two-stage surgery (T1).

Study Overview

Detailed Description

Initially, 48 patients were recruited from new referrals to the Lab of Preventive Dentistry, Periodontology and Implant Biology, Aristotle University of Thessaloniki (AUTh) for surgical placement of at least one implant located in the upper/lower jaw in the anterior/posterior segment.

Study design An initial screening visit included full-mouth periodontal assessment, radiographic examination, fulfillment of inclusion/exclusion criteria and suitable patients (n=48) were randomised into either treatment Group; in the control Group (Group-A), a conventional surgical protocol was followed for implant placement, while in the test Group (Group-B) implants were placed in conjunction with an autologous CTG. Each Group was further categorized as having thin mucosa (≤2.5mm for Subgroups-AI/-BI) or thick mucosa (>2.5mm for Subgroups-AII/-BII) at the implantation site before implant placement (baseline=T0). Implants were exposed 3-4 months later (T1).

Surgical procedures A single implant system (Osseotite, Certain, parallel wall, Biomet 3i, Florida, USA; implants of 3.25/4.0 mm in diameter) was used in all cases. At T0, following local anaesthesia (lidocaine hydrochloride 2%, epinephrine 1:100000, Lignospan standard, Septodont, France), crestal incisions were performed and full-thickness flaps were raised for implant placement. Implants were placed at the level of the alveolar crest following the manufacturer's surgical guidelines and a two-stage protocol. Flaps were repositioned using absorbable sutures (polygalactic acid 5/0 sutures; PGA, medipac, Greece). In Group-B, a similar protocol was followed as in Group-A, with the exception that following implant placement a CTG was harvested from the palate, between the maxillary canine and the first molar (Liu & Weisgold, 2002) and was stabilised onto the lingual flap using a horizontal mattress suture. Standardised dimensions of the CTG (11×6×1.5mm) were sought to cover the implant's shoulder and extend 3-5 mm on the buccal and the lingual aspect of the alveolar ridge (Fig. 1). Scoring of the periosteum for coronal advancement of the flaps was mainly performed in Group-B (16 of 23 cases).

Post-operative care Post-operative pain and oedema were controlled by Ibuprofen, 600 mg. All participants were prescribed antibiotics (Amoxicillin, 500 mg per 8 hours for 5 days) and were instructed to rinse twice daily with chlorhexidine digluconate (0.12%) and to abstain from oral hygiene in the test area for one week. Any post-operative adverse events (i.e. swelling, suppuration, flap dehiscence, persistent pain) were recorded upon suture removal ten days after surgery.

Clinical assessments

The following clinical assessments were performed at the implant site at T0 and were repeated at T1:

A periodontal probe (Hu-Friedy XP-23/QW) that had an endo-stop attached on it was used to determine the distances which were finally measured in millimetres by a digital calliper (Mitutoyo Europe GmbH) for precision.

Mucosa thickness (mm) was measured by bone sounding on the alveolar crest and at 2- and 4 mm apically, both on the buccal and the lingual aspects.

The WKT (mm) was measured on the mid-buccal aspect of the implant site. The Implant to Bone Crest (I-BC) distance (mm) was measured at four sites, mid-buccally, mid-lingually, mesially and distally and was determined as the distance of the osseous crest from the implant platform.

The Thickness of the buccal and lingual bone (mm) was measured at the level of the implant shoulder and at 3- and 6 mm apically, using a customised metallic calliper (Ustomed, Tuttlingen, Germany). The inner part of one jaw firmly touched the periphery of the screw hole within the implant fixture and the opposing jaw firmly touched the osseous surface of the alveolar ridge at the predetermined depth.

Radiographic assessment Intraoral digital radiography and the VixWin™ Platinum Gendex software (Hatfield, PA, USA) was utilised to linearly assess the I-BC distance on the mesial/distal aspect at T0 and T1. The long-cone paralleling technique was used at a distance of 10 cm between the x-ray head and the digital sensor which was attached to a custom-made silicone bite block for reproducible radiographs.

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • above 18 years of age
  • no active periodontal disease (Plaque Index ≤15%, Gingival Index ≤20%, <20% of sites equal to or deeper than 5mm).

Exclusion Criteria:

  • medical conditions that contraindicated surgical implant placement,
  • medication that interfered with bone metabolism,
  • pregnancy or lactation,
  • inadequate dimensions of the alveolar ridge or grafted bone at the surgical site,
  • tooth extraction 3 months prior to the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Conventional Implant placement
conventional implant placement following the manufacturer's instructions
Implants were placed following teh manufacturer's instructions
Experimental: Implant and Connective tissue grafting
implant placement in combination with connective tissue grafting
A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mucosa thickness
Time Frame: implant placement to implant exposure
measured by bone sounding on the alveolar crest and at 2- and 4 mm apically, both on the buccal and the lingual aspects
implant placement to implant exposure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Width of keratinised mucosa
Time Frame: Implant placement to implant exposure
measured on the mid-buccal aspect of the implant site
Implant placement to implant exposure
Implant to Bone Crest (I-BC) distance
Time Frame: Implant placement to implant exposure
measured at four sites, mid-buccally, mid-lingually, mesially and distally and was determined as the distance of the osseous crest from the implant platform.
Implant placement to implant exposure
Thickness of the buccal and lingual bone
Time Frame: Implant placement to implant exposure
measured at the level of the implant shoulder and at 3- and 6 mm apically, using a customised metallic calliper (Ustomed, Tuttlingen, Germany). The inner part of one jaw firmly touched the periphery of the screw hole within the implant fixture and the opposing jaw firmly touched the osseous surface of the alveolar ridge at the predetermined depth.
Implant placement to implant exposure
radiographic Implant to Bone Crest (I-BC) distance
Time Frame: Implant placement to implant exposure
Intraoral digital radiography and the VixWin™ Platinum Gendex software (Hatfield, PA, USA) was utilised to linearly assess the I-BC distance on the mesial/distal aspect at T0 and T1. The long-cone paralleling technique was used at a distance of 10 cm between the x-ray head and the digital sensor which was attached to a custom-made silicone bite block for reproducible radiographs.
Implant placement to implant exposure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2014

Primary Completion (Actual)

April 30, 2016

Study Completion (Actual)

July 30, 2016

Study Registration Dates

First Submitted

October 31, 2018

First Submitted That Met QC Criteria

October 31, 2018

First Posted (Actual)

November 2, 2018

Study Record Updates

Last Update Posted (Actual)

November 5, 2018

Last Update Submitted That Met QC Criteria

November 1, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • AUTh_5/30-09-2014

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dental Implant Placement

Clinical Trials on Implant placement

3
Subscribe